-
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
•
Apeiron Therapeutics, a biomarker-driven cancer therapy developer with operations in Shanghai, China, and San Francisco, US, has announced the enrollment of the first patient in the Phase Ia/B study for its investigational drug GTA182. The dosage escalation study aims to assess the safety, efficacy, and pharmacokinetics of the small molecule…
-
China Releases Comprehensive AI Application Guidelines for Healthcare Industry
•
The National Health Commission, National Administration of Traditional Chinese Medicine, and National Bureau of Disease Control and Prevention have jointly published the “Reference Guidelines for Artificial Intelligence (AI) Application Scenarios in the Healthcare Industry.” These guidelines provide a comprehensive framework for the integration of AI across various sectors within the…
-
Insilico Medicine Secures Revolving Loan Facility with HSBC to Boost Drug Discovery Pipeline
•
China-based artificial intelligence (AI) drug developer Insilico Medicine has announced the establishment of a Revolving Loan Facility of up to USD 100 million with HSBC, a leading global bank and financial services institution. This customized financing solution is designed to support the expansion of Insilico’s proprietary novel drug discovery pipeline…
-
GSK and Cambridge University Forge £50 Million Partnership to Tackle Immune Diseases
•
UK pharmaceutical giant GSK plc (LON: GSK, NYSE: GSK) has unveiled a significant five-year partnership with the University of Cambridge and Cambridge University Hospitals, backed by a financial commitment of £50 million. This collaboration aims to enhance research and development efforts targeting immune-related diseases. Dubbed the Cambridge-GSK Translational Immunology Collaboration…
-
Huawei Partners with Medical University Hospital to Boost Healthcare Innovation
•
The Affiliated Hospital of Xuzhou Medical University has entered into a comprehensive partnership with Huawei Technologies Co., Ltd., a leading global provider of information and communications technology (ICT) solutions. Under this alliance, Huawei will offer a suite of advanced technologies, including network connectivity, transportation support, diverse computing power products, intelligent…
-
Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development
•
Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked three strategic agreements with California-based Insitro, a company at the forefront of machine-learning driven drug development. This collaboration aims to forge ahead with new therapies for metabolic diseases, with a particular focus on metabolic dysfunction-associated…
-
XtalPi’s AI Platform XtalFold Secures Licensing Deal with Janssen Biotech, Enhancing Biologics Discovery
•
XtalPi Inc., a leading AI-driven drug discovery firm based in Shenzhen and known as QuantumPharm Inc. (HKG: 2228), has announced a significant licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, for its proprietary AI platform, Ailux Biologics’ XtalFold. This platform, recognized for its innovative approach in…
-
Insilico Medicine and Seto Biopartner to Leverage AI in Synthetic Biology and Drug Discovery
•
Insilico Medicine has announced a strategic partnership with Seto Bio (SHE: 300583) to harness cutting-edge AI technology to explore and optimize key steps in the engineering transformation of biological systems, advancing synthetic biology research and innovative drug development. Established in 2014, Insilico Medicine has built over 30 proprietary drug pipeline…
-
ClouDr Receives NMPA Green Light for ClouDT-01, a Groundbreaking Digital Diabetes Treatment
•
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the banner of “ClouDr” on the Hong Kong stock exchange (HKG: 9955), has announced that it has secured marketing approval from the National Medical Products Administration (NMPA) for its innovative digital medicine product, ClouDT-01, designed for the treatment of diabetes. Leveraging…
-
Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study
•
China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its Phase IIa study for ISM001-055, an in-house generative AI-generated drug candidate for idiopathic pulmonary fibrosis (IPF). The molecule, which targets TNIK (Traf2- and NCK- interacting kinase), has shown a positive safety profile and dose-dependent lung…
-
Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery
•
Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an expansion of their partnership to harness generative artificial intelligence (AI) for drug discovery. While the financial details of the deal remain undisclosed, the collaboration aims to combine Sino Bio’s advanced protein expression and wet-lab expertise…
-
Beijing’s MoleculeMind Secures Series A Funding to Accelerate AI Protein Design Innovations
•
MoleculeMind, a Beijing-based AI protein design platform, has reportedly secured a Series A financing round, raising hundreds of millions of renminbi. The funding was co-led by Cherami Investment and Shenzhen Capital Group, with participation from Sense Capital and EBI Investment. The capital raised will be directed towards enhancing the company’s…
-
Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy
•
Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on organoid disease models and artificial intelligence (AI), has entered into a strategic partnership with Guangzhou Jennio Biotech Co., Ltd. The collaboration aims to leverage organoid disease models and advance tumor immunotherapy drug development. Financial specifics…
-
Insilico Medicine Partners with Inimmune Corporation to Utilize AI for Immunotherapy Innovation
•
Insilico Medicine, a leading artificial intelligence-driven drug discovery company based in China, has announced a strategic research collaboration agreement with Inimmune Corporation, a U.S. biotechnology firm specializing in immunotherapy and vaccine innovation. Under the terms of the agreement, Inimmune will utilize Insilico’s proprietary generative AI platform, Chemistry42, to accelerate the…
-
Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has entered into a research collaboration with Genetic Leap, a U.S. biotech firm specializing in artificial intelligence (AI) and RNA genetic medicine. This partnership expands on a previously successful pilot and will see Genetic Leap apply…
-
AI-Driven Drug Firms Recursion and Exscientia to Merge in a Deal Valued at Approximately USD 850 Million
•
Recursion (NASDAQ: RXRX), a U.S.-based clinical-stage TechBio company, and Exscientia plc (NASDAQ: EXAI), a U.K.-headquartered artificial intelligence (AI)-driven drug design and development firm, have announced a definitive agreement to merge. The combined entity will retain the name Recursion, with its headquarters in Salt Lake City, Utah, and will continue to…
-
Innovent Biologics Partners with Wecomput Technology to Accelerate AI in Drug Development
•
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered into a strategic partnership with Wecomput Technology Co., Ltd, a prominent computational contract research organization (CRO) in China with a global footprint. The collaboration aims to harness the power of artificial intelligence (AI) to enhance…
-
Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328
•
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug candidate AFN0328. This investigational mRNA drug targets tumors associated with human papillomavirus (HPV), particularly HPV16 and/or HPV18 in the cervix, which are…
-
E-Health Now Secures USD 13.8 Million in Series C Financing to Expand AI Medical Services
•
E-Health Now, a China-based one-stop artificial intelligence (AI)-powered medical health service platform, has reportedly secured nearly RMB 100 million (USD 13.8 million) in a Series C financing round. The funding round attracted notable investors such as Ameba Capital, Ventech China, and Borchid Capital. The capital raised is intended to fuel…
-
Hisense Medical Teams Up with Tianjin Government and Yujin AI for Intelligent Medical R&D
•
Hisense Medical Equipment Co., Ltd, a leading medical equipment provider based in China, has entered into a strategic partnership agreement with the government of Tianjin Binhai New Area and fellow Chinese firm Tianjin Yujin Artificial Intelligence Medical Technology Co., Ltd. The collaboration aims to establish an intelligent medical equipment technology…
-
Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery
•
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has announced a drug collaboration agreement with OpenAI, a prominent artificial intelligence (AI) research organization headquartered in San Francisco. As part of this collaboration, Lilly will utilize OpenAI’s advanced generative AI technologies to develop innovative antimicrobial…
-
Jiangsu Yuyue Medical Teams Up with China Unicom for Digital Healthcare Innovation
•
Shanghai-based Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223) has announced a strategic partnership with China Unicom, aiming to enhance digitalization in enterprise management, product digitization, and global technological empowerment. China Unicom will utilize its network, cloud, communication technology, and AI algorithms to advance the intelligence and digital upgrade of Yuyue’s…
-
GSK Partners with Ochre Bio to Access Liver Data for Hepatology Therapy Development
•
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow UK biotechnology firm Ochre Bio, announcing this week that it will pay up to USD 37.5 million for access to Ochre Bio’s human liver data. This strategic collaboration aims to bolster the development of hepatology…
-
Sanofi Partners with Bluecrux to Enhance Supply Chain with AI Technologies
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, is enhancing its supply chain strategy with artificial intelligence-based technologies provided by Bluecrux, a consulting and technology firm based in Belgium. Bluecrux’s solution consolidates all of Sanofi’s data systems into a unified model, enabling comprehensive end-to-end visibility across the company’s supply chain.…
-
AI in Pharma: MindRank Ltd Joins Forces with Zhejiang Hisun Pharmaceutical for Drug R&D
•
MindRank Ltd, a China-based artificial intelligence (AI)-driven drug development company, has entered into a strategic partnership with domestic pharmaceutical firm Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267). The collaboration will combine MindRank’s AI platform technology with Hisun Pharmaceutical’s research and development (R&D) capabilities and manufacturing resources to advance the field…
-
Sanofi Leads Pharma Industry with AI Collaboration with Formation Bio and OpenAI
•
Sanofi (NASDAQ: SNY), the France-based multinational pharmaceutical company, has announced a cutting-edge collaboration with US firms Formation Bio and OpenAI to develop customized artificial intelligence (AI) models designed to expedite drug development. While the financial specifics of the agreement were not disclosed, the partnership signifies Sanofi’s strategic commitment to leveraging…
-
Union Hospital Teams Up with Baidu Health for AI-Enhanced Outpatient Services
•
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has entered into a strategic partnership with Baidu Health. This collaboration aims to focus on AI intelligent outpatient services, thereby strengthening the digital transformation of medical services. The hospital has demonstrated initial success with its AI intelligent outpatient system,…
-
Siemens Healthineers and Ruijin Hospital Collaborate to Build Medical Digital Human Metaverse
•
Siemens Healthineers AG, the German medical technology major, has entered into a strategic partnership with Ruijin Hospital, a Class 3A teaching hospital based in Shanghai. The collaboration aims at developing “Medical digital human metaverse application scenarios,” marking a significant step in the integration of metaverse technology into healthcare. Siemens Healthineers…
-
AstraZeneca and BenevolentAI Reach Milestone in Heart Failure Target Validation
•
AstraZeneca (AZ; NASDAQ: AZN) has announced the successful experimental validation of a groundbreaking heart failure target discovered by BenevolentAI (AMS: BAI), a UK-based precision drug design company. This milestone achievement marks a significant step in their ongoing partnership, which was initially established in 2019 with a focus on idiopathic pulmonary…
-
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
•
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ: AZN), Bristol Myers Squibb (BMS; NYSE: BMY), and Takeda (NYSE: TAK). These partnerships underscore the biotech company’s commitment to leveraging its integrated AI and wet-lab technologies for the design of conformation- and target-selective antibody candidates.…
-
Subtle Medical Inc Closes USD 10 Million Series B+ Round to Accelerate Global Expansion
•
Subtle Medical Inc, a medical imaging specialist and Stanford University spin-off, has reportedly raised close to USD 10 million in a Series B+ financing round. The financing was backed by investors including Shanghai-based Wenzhou Capital, Fusion Fund, ENVISIONX Capital, Bluerun Ventures, and other strategic partners across the Asia Pacific region.…
-
Xi and Macron Discuss Enhanced Market Access for Foreign Investors, Focus on Life Sciences
•
This week, talks between China’s President Xi Jinping and France’s President Emmanuel Macron in France resulted in commitments to further open markets for foreign investors, particularly in the life sciences sector. President Xi emphasized the potential for increased trade and cooperation across several industries, specifically advocating for higher-value high-tech exports…
-
Insilico Medicine Partners with invoX Pharma to Boost AI-Driven Drug Discovery
•
China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with compatriot firm invoX Pharma, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177). The collaboration aims to combine Insilico’s AI and computer-aided drug discovery expertise, including its proprietary PandaOmics target discovery engine, with invoX’s innovative drug…
-
Kingmed Diagnostics Partners with GenStar Biosolutions to Develop Auto-Antibody Immunofluorescence AI Software
•
Kingmed Diagnostics, a leading independent medical laboratory based in Guangdong, has entered into a strategic partnership with GenStar Biosolutions Co., Ltd, a Beijing-headquartered specialist in immune diagnostic technology. The collaboration aims to jointly develop auto-antibody immunofluorescence AI interpretation software and create an integrated, intelligent immunofluorescence detection platform. Financial details of…
-
Shanghai Unveils Massive Investment Projects and Funds to Boost High-Tech Industries
•
Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost for key industries in the region. In the first quarter of 2024, a total of 420 major investment projects, each valued at over RMB 100 million (USD 13.8 million), were executed, culminating in a total…
-
AstraZeneca’s Tralokinumab Trial Data Spurs Development of Brainomix’s e-Lung Software
•
AstraZeneca (AZ; NASDAQ: AZN) has reported data from a Phase II trial for its idiopathic pulmonary fibrosis (IPF) candidate, tralokinumab, which has contributed to the development of Brainomix’s e-Lung software. This AI-enabled tool, announced by the UK medtech company this week, is designed to identify patients at risk of decline…
-
Edan Instruments Partners with Global Health Labs to Develop AI-Enhanced Handheld Ultrasound
•
Shenzhen-based Edan Instruments Inc. has forged a strategic partnership with Global Health Labs Inc. to collaboratively develop an AI-driven, cost-effective handheld ultrasound device, leveraging their combined expertise and cutting-edge technology resources. This alliance aims to innovate handheld ultrasound technology by integrating artificial intelligence, making it accessible and affordable for grassroots…
-
CAIR Launches CARES Copilot 1.0: A Revolutionary AI Chatbot for Medical Diagnosis and Treatment
•
The Centre for Artificial Intelligence and Robotics (CAIR), part of the Chinese Academy of Sciences (CAS) in Hong Kong, has officially launched CARES Copilot 1.0, a cutting-edge chatbot powered by a large language model designed to assist medical professionals in diagnosis and treatment. CARES Copilot 1.0 integrates the vast knowledge…
-
C&Y Pharmaceutical Teams Up with GigaCeuticals to Form AI-Driven Drug Development JV
•
Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254), a Chinese pharmaceutical company, is venturing into a joint venture (JV) with Beijing-based AI-driven drug developer GigaCeuticals. The new JV, valued at RMB 120 million (USD 16.7 million), aims to collaborate on the research and development, industrialization, and commercialization of innovative drugs…
-
BioGeometry and Sanyou Biopharmaceuticals Forge AI Partnership for Antibody Drug Discovery
•
BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou Biopharmaceuticals Co., Ltd. The collaboration aims to harness their combined expertise in generative AI technology for target discovery, with the goal of developing IND-stage drugs and creating an advanced AIGC-driven antibody drug discovery platform. The…
-
Biden’s Executive Order May Restrict Data Access for China-Based Life Science Firms in the US
•
US President Joe Biden last week issued an Executive Order titled “Preventing Access to Americans’ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern,” which may present new challenges for China-based life science companies operating in the United States. The order is designed to curb the…
-
Baidu Health Partners with Souyao to Boost Offline Pharmacy Services in China
•
Baidu Health has entered into a partnership with Beijing-based pharmaceutical business service provider Souyao. The collaboration will capitalize on Baidu’s resource advantages in areas such as search engines, map navigation, health services, artificial intelligence (AI), and e-commerce to offer comprehensive technical and operational services for brick-and-mortar pharmacies. The goal is…
-
MindRank Ltd Partners with Henlius Biotech to Pioneer AI-Powered Drug Therapies
•
MindRank Ltd, a China-based frontier in AI-enabled drug development, has inked a strategic partnership with Shanghai Henlius Biotech Inc. (HKG: 2696), a fellow Chinese firm, to co-develop AI-driven antibody drug conjugate (ADC) and anti-aging therapy platforms. This alliance combines Henlius’s comprehensive biopharmaceutical platform, specialized in antibody and Linker Payload technologies,…
-
Siemens Healthineers AG and Shandong First Medical University’s College of Radiology Collaborate on Medical Imaging Metaverse
•
Siemens Healthineers AG (ETR: SHL), a leading life sciences company based in Germany, has entered into a strategic partnership with the College of Radiology at Shandong First Medical University. The collaboration aims to encompass several key initiatives: The duo will jointly construct China’s inaugural “Medical Imaging Metaverse Immersive Teaching and…
-
Kingmed Diagnostics and MegaRobo Technologies Join Forces to Pioneer Smart Medical Laboratories
•
Kingmed Diagnostics (SHA: 603882), a prominent independent medical laboratory headquartered in Guangdong, is poised to form a joint venture (JV) with MegaRobo Technologies, a Beijing-based firm renowned for its integration of robotics and artificial intelligence (AI) in life sciences. This strategic partnership aims to pioneer industry-standard medical laboratory automation solutions,…
-
MSD Partners with Variational AI to Harness Generative AI for Drug Discovery
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian company Variational AI to leverage the latter’s generative AI-powered model for drug discovery initiatives. Through this partnership, MSD will have early access to Variational AI’s platform, which utilizes text prompts to generate novel small molecules…
-
Convalife Pharmaceuticals and Divamics Inc. Join Forces to Advance Drug Discovery with AI
•
Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing in artificial intelligence (AI), quantum mechanics, and molecular simulation algorithms, have announced a strategic partnership agreement. This collaboration aims to revolutionize the drug discovery process by combining cutting-edge AI capabilities with advanced molecular dynamics simulation.…
-
Meinian Onehealth Collaborates with Huawei Cloud and Runda Medical on AI Health Robot
•
Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a strategic partnership with Huawei Cloud and Shanghai Runda Medical Science and Technology Co., Ltd (SHA: 603108) to develop “Healthy Little Beauty,” a health management artificial intelligence (AI) robot. This initiative marks the creation of China’s first AI robot…
-
Sun Yat-sen University Researchers Develop AI Model for Early Ovarian Cancer Detection
•
Researchers at Guangzhou’s Sun Yat-sen University Cancer Center have made a significant breakthrough with the development of an artificial intelligence (AI)-based model designed for the early detection of ovarian cancer. This cost-effective AI model aims to assist in diagnosing the deadliest form of gynecological cancer worldwide. In China, early-stage diagnosis…
-
NVIDIA Expands Healthcare Reach with Amgen’s deCode Partnership at JP Morgan Conference
•
At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a new collaboration with Amgen (NASDAQ: AMGN)’s subsidiary, deCode. This partnership will see deCode leverage NVIDIA’s advanced supercomputers and the BioNeMo generative artificial intelligence (AI) platform to bolster the development of its genomic foundational models. BioNeMo,…
-
Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis
•
Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ: GOOGL), has entered into its inaugural pharmaceutical collaborations, signing separate agreements with Eli Lilly (NYSE: LLY) and Novartis (NYSE: NVS). These partnerships are aimed at discovering small-molecule therapeutics for multiple undisclosed targets. Under the terms…
-
Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate
•
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with China’s Insilico Medicine to develop a KAT6A inhibitor originating from Insilico’s AI-driven platform. The candidate, targeted for hormone-sensitive cancers and other oncological indications, shows promise as a potent KAT6A inhibitor based on preclinical data. KAT6A,…
-
Baidu Health and Chongqing’s Fifth People’s Hospital Collaborate on Integrated Medical Services
•
Baidu Health has entered into a partnership with the Fifth People’s Hospital of Chongqing, a Class 3A general hospital in China. The collaboration aims to combine the hospital’s disciplinary and location advantages with Baidu Health’s strengths in online diagnosis, treatment, digitalization, and artificial intelligence (AI) to establish an integrated online-offline…
-
Sanofi Broadens Collaboration with Exscientia, Licensing New Precision Drug Program
•
French pharmaceutical giant Sanofi (NASDAQ: SNY) has expanded its partnership with UK-based AI-driven precision drug design company Exscientia (NASDAQ: EXAI) by in-licensing a program in an undisclosed therapeutic area. This move builds on a 2022 agreement aimed at developing up to 15 novel small-molecule candidates across oncology and immunology. The…
-
MSD Partners with Owkin to Develop MSI-H Biomarker Screening for Cancers
•
US pharmaceutical company Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a partnership with French firm Owkin to develop and commercialize a pre-screening procedure for identifying the microsatellite instability- (MSI) H biomarker in various cancers. The initiative aims to test for MSI-H in endometrial, gastric, small intestinal, and…
-
Reetoo Biotechnology Boosts AI in Medical Diagnostics with $14 Million Funding Round
•
Shenzhen Reetoo Biotechnology Co., Ltd, a Chinese firm at the forefront of integrating artificial intelligence with medical diagnostics, has reportedly secured over RMB 100 million (USD 14 million) in a Series B2 financing round. The round was led by CAS Investment and a prominent Chinese fund, with additional participation from…
-
MSD to Migrate IT Systems to AWS, Aiming for Faster Drug Discovery and Clinical Trials
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced plans to transition a significant portion of its IT infrastructure to Amazon Web Services (AWS), a move aimed at enhancing efficiency in drug discovery and clinical trial development. This multiyear initiative, revealed by parent company Amazon (NASDAQ: AMZN) this week, will…
-
Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD
•
Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of a clinical study for its potential first-in-class PHD inhibitor, ISM5411, targeting inflammatory bowel disease (IBD). ISM5411 is an intestinal-restricted small-molecule inhibitor developed using Insilico’s Pharma.AI platform, featuring a novel molecular framework and a unique binding…
-
Boehringer Ingelheim Partners with Phenomic AI to Target Stroma-Rich Cancers
•
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic AI to leverage the latter’s single-cell transcriptomics platform for the discovery of drug targets in stroma-rich cancers, including colorectal and pancreatic tumors. In return for the option to license the identified targets and secure development…
-
Xiamen Inno Medical Partners with Olympus to Advance AI in Digestive Endoscopy
•
Xiamen Inno Medical Technology Co., Ltd., a China-based specialist in artificial intelligence (AI) powered digestive endoscopy, has entered into a partnership with Olympus Corporation, a major player in the digestive endoscopy field. The collaboration aims to explore innovative applications and development of AI technology within the digestive endoscopy sector. Financial…
-
Genentech and NVIDIA Collaborate to Advance Drug Discovery with AI
•
Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has entered into a collaboration agreement with semiconductor manufacturer NVIDIA (NASDAQ: NVDA) to expedite drug discovery and development. This partnership aims to harness the power of artificial intelligence (AI) by integrating Genentech’s biological and molecular datasets with NVIDIA’s advanced supercomputing…
-
XtalPi Inc. and Singapore’s EDDC Broaden Collaboration in AI-Driven Drug Discovery
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a memorandum of understanding (MOU) with the Experimental Drug Development Centre (EDDC) in Singapore to form a collaborative partnership. The two entities have pledged to expand their collaboration to include the application of automated synthesis experiments and large language models…
-
AstraZeneca Launches Evinova to Enhance Global Clinical Development with Digital Health Solutions
•
UK-based AstraZeneca (AZ; NASDAQ: AZN) has launched Evinova, a digital health solutions provider, with the aim of supporting global clinical development. Evinova offers AI-enabled technologies and services to clinical trial (CT) sponsors, clinical research organizations (CROs), CT site care teams, and patients. The new business unit will initially focus on…
-
Winning Health Partners with Shanghai Seventh People’s Hospital on Medical AI Services
•
Shanghai-based medical information industry player, Winning Health (SHE: 300253), has announced a partnership with Shanghai Seventh People’s Hospital to focus on medical artificial intelligence (AI) services. Collaboration on Medical AI Development and ApplicationThe collaboration aims to deepen research and development, application, and implementation of medical AI technologies. Together, Winning Health…
-
Amgen Partners with PostEra for Small-Molecule Drug Discovery Initiative
•
Biopharmaceutical company Amgen (NASDAQ: AMGN) has entered into a drug discovery collaboration with US-based PostEra, covering up to five small-molecule programs. As part of the agreement, Amgen will also secure a future option to leverage PostEra’s AI technology for its own pipeline development. Financial Details and PostEra’s Track RecordWhile the…
-
Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology
•
Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration with US biotechnology firm Recursion Pharmaceuticals (NASDAQ: RXRX). The partnership, which was initially focused on fibrosis, will now shift its attention to precision oncology. This strategic move will see the initiation of up to seven…
-
Suzhou Porton Biologics Partners with BioMap to Enhance AAV Vector Design in Gene Therapy
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with US biotech company BioMap, an AI-based drug discovery platform co-founded by Baidu’s CEO Robin Li and Baidu Ventures CEO Wei Liu. This collaboration aims to develop an AAV assembly efficiency model…
-
Sun Yat-sen Memorial Hospital Partners with Siemens Healthineers on Metaverse Visualization Surgery
•
China’s Sun Yat-sen Memorial Hospital, affiliated with Sun Yat-sen University, has entered into a strategic partnership with Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) at the 6th China International Import Expo (CIIE) in Shanghai. The collaboration focuses on the science research, application, and translation of metaverse visualization surgery,…
-
XtalPi Inc. and CK Life Sciences Expand Partnership to Develop AI-Powered Cancer Diagnostics
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has announced a strategic partnership agreement with China-based CK Life Sciences (HKG: 0775). The collaboration aims to leverage AI and clinical diagnosis data, including biomarker information from cancer patients and healthy populations, to develop molecular diagnostic models that predict cancer prognosis risk based…
-
AstraZeneca Licenses Nanoform’s Starmap AI Platform to Enhance Drug Development
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has obtained a license from Finnish drug design expert Nanoform Finland (HEL: NANOFH) for Starmap, an innovative AI-enabled platform. This platform facilitates confidential in silico testing of molecule candidates prior to chemical synthesis, aiming to reduce clinical attrition throughout the drug development pipeline.…
-
Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a smart Artificial Intelligence (AI) Q&A bot for its antiviral drug Yueruiling (leritrelvir). This AI-driven platform is designed to enhance patient support by providing smart Q&A services, an offline drug purchase map guide, and a comprehensive…
-
Baidu Launches Interactive AI Medication Instructions Service at Baidu World 2023
•
Robin Li, CEO of China-based internet services giant Baidu, unveiled an innovative interactive AI medication instructions service during the Baidu World 2023 conference earlier this week. This groundbreaking product is the first of its kind in China, designed to utilize the ERNIE GPT bot and Digital Human novel models. The…
-
Sanofi Partners with BioMap to Accelerate AI-Driven Drug Discovery
•
France-based pharmaceutical giant Sanofi (EPA: SAN) has entered into a strategic partnership with US biotech firm BioMap, an AI-driven drug discovery platform founded by Robin Li, CEO of Chinese internet leader Baidu (NASDAQ: BIDU; HKG: 9888), and Wei Liu, CEO of Baidu Ventures. The collaboration includes an upfront payment of…
-
Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091
•
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement with US firm Exelixis Inc., (NASDAQ: EXEL), granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1. USP1 has been identified as a synthetic lethal target in the…
-
EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies
•
Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the formation of a strategic research collaboration agreement to co-develop innovative therapeutics for novel targets in inflammatory diseases of the gastrointestinal (GI) system and liver. The collaboration aims to leverage the combined expertise of both companies…
-
Eurofarma Invests in Abcuro as Part of $100 Million Disruptive Startups and Biotech Initiative
•
Brazil-based multinational company (MNC) Eurofarma has announced an investment in US immunotherapy developer Abcuro as part of a broader program to invest up to USD 100 million in potentially disruptive startups and biotechnology companies in the discovery and development phase. This 5-year project aims to support up to 25 companies…
